CLK1 and Duchenne muscular dystrophy: Pharmacological inhibition of CLK1 has been investigated pre-clinically (in mice) for the treatment of Duchenne muscular dystrophy—it resulted in enhanced mutated exon 31 skipping, which led to the production of functional exon 31 skipped dystrophin in cells derived from Duchenne muscular dystrophy patients [127].